Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Ophthalmology. Retina|May 4, 2019
Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL StudyMichael Larsen, Sebastian M Waldstein, Siegfried Priglinger, et al.
Ophthalmology|August 16, 2017
Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER StudyRamin Tadayoni, Sebastian M Waldstein, Francesco Boscia, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2023
Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extensionStephen L Hauser, Ronald Zielman, Ayan Das Gupta, et al.
Frontiers in Physiology|November 12, 2020
Continuous, Automated Breathing Rate and Body Motion Monitoring of Rats With Paraquat-Induced Progressive Lung InjurySzczepan W Baran, Ayan Das Gupta, Maria A Lim, et al.
Annals of the Rheumatic Diseases|January 25, 2019
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trialsStefan Schreiber, Jean-Frederic Colombel, Brian G Feagan, et al.
The Journal of Rheumatology|March 16, 2021
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III StudiesGeorg Schett, Xenofon Baraliakos, Filip Van den Bosch, et al.
ACR Open Rheumatology|May 1, 2020
Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 StudiesAtul A Deodhar, Corine Miceli-Richard, Xenofon Baraliakos, et al.
CNS Drugs|March 2, 2022
Population Pharmacokinetic-B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple SclerosisHuixin Yu, Gordon Graham, Olivier J David, et al.
Neurology and Therapy|July 14, 2023
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis TreatmentStephen L Hauser, Ludwig Kappos, Amit Bar-Or, et al.
Neurology and Therapy|March 14, 2022
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with OfatumumabAnne H Cross, Silvia Delgado, Mario Habek, et al.
Pageof 2